KOD

Kodiak Sciences Inc.
NASDAQ

Real-time Quotes | Nasdaq Last Sale

61.60
+0.02
+0.03%
After Hours: 60.56 -1.04 -1.68% 16:11 05/22 EDT
OPEN
61.81
PREV CLOSE
61.58
HIGH
62.80
LOW
59.33
VOLUME
240.98K
TURNOVER
--
52 WEEK HIGH
82.75
52 WEEK LOW
8.95
MARKET CAP
2.74B
P/E (TTM)
-39.0863
1D
5D
1M
3M
1Y
5Y

Analyst Rating

Based on 9 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target

The average KOD stock price target is 83.19 with a high estimate of 115.00 and a low estimate of 63.00.

EPS

KOD News

More
SunTrust Robinson Humphrey Maintains Buy on Kodiak Sciences, Lowers Price Target to $90
SunTrust Robinson Humphrey maintains Kodiak Sciences (NASDAQ:KOD) with a Buy and lowers the price target from $101 to $90.
Benzinga · 05/14 15:07
Kodiak Sciences Inc. (KOD) CEO Victor Perlroth on Q1 2020 Results - Earnings Call Transcript
Seeking Alpha - Transcript · 05/13 05:51
Kodiak Sciences Inc. 2020 Q1 - Results - Earnings Call Presentation
Seeking Alpha - Article · 05/13 01:00
Kodiak Sciences to Present at the Bank of America Merrill Lynch Health Care Conference
Kodiak Sciences Inc. (Nasdaq: KOD), a clinical stage biopharmaceutical company developing novel therapeutics to treat chronic, high-prevalence retinal diseases, today announced that management will present at the virtual Bank of America Merrill Lynch Health Ca
PR Newswire · 05/11 20:13
Kodiak Sciences Earlier Reported Q1 EPS $(0.540) Down From $(0.210) YoY
Kodiak Sciences (NASDAQ:KOD) reported quarterly losses of $(0.540) per share. This is a 157.14 percent decrease over losses of $(0.210) per share from the same period last year.
Benzinga · 05/11 15:03
Kodiak Sciences EPS misses by $0.04
Kodiak Sciences (NASDAQ:KOD): Q1 GAAP EPS of -$0.54 misses by $0.04. Cash, cash equivalents and marketable securities of $430.39M Press Release
seekingalpha · 05/11 14:33
Kodiak Sciences Announces First Quarter 2020 Financial Results and Recent Business Highlights
Kodiak Sciences Inc. (Nasdaq: KOD), a clinical stage biopharmaceutical company specializing in novel therapeutics to treat chronic, high-prevalence retinal diseases, today reported business highlights and financial results for the first quarter ended March 31,
PR Newswire · 05/11 09:30
Kodiak Sciences to Host First Quarter 2020 Business Highlights Webcast on May 12, 2020
PR Newswire · 05/08 21:30

Industry

Biotechnology & Medical Research
+1.01%
Pharmaceuticals & Medical Research
+0.05%

Hot Stocks

Symbol
Price
%Change

About KOD

Kodiak Sciences Inc. is a clinical stage biopharmaceutical company. The Company is focused on developing therapeutics to treat ophthalmic diseases. The Company’s Antibody Biopolymer Conjugate (ABC) platform focuses on merging the fields of antibody-based and chemistry-based therapies. The Company in addition to its lead product candidate, KSI-301, is a molecule for age-related macular degeneration and diabetic retinopathy. The Company has leveraged its ABC platform to build a pipeline of product candidates in various stages of development including KSI-501, a dual inhibitor ABC for the treatment of neovascular retinal diseases, such as wet AMD and diabetic retinopathy.
More

Webull offers kinds of Kodiak Sciences Inc stock information, including NASDAQ:KOD real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, KOD stock news, and many more online research tools to help you make informed decisions.